HOUSTON & FARGO, N.D.--(BUSINESS WIRE)--Dec. 19, 2005--CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced positive results of a pilot study using CytoGenix synDNA(TM) as the active ingredient in a Hepatitis B vaccine, demonstrating that it is highly effective in generating an immune response.
